News Releases

Year

May 15, 2020

UroGen Pharma Announces First Presentation of Data from Phase 2b Study of UGN-102 in Patients with Difficult to Treat Type of Bladder Cancer

65% Complete Response in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer Of Patients who Achieved a Complete Response and Underwent an Evaluation at Each Timepoint, 97%, 86% and 85% Remained Disease Free at Six, Nine and 12 Months Following Initiation of Therapy,

May 15, 2020

UroGen Announces Positive Data from Pivotal OLYMPUS Trial Evaluating Jelmyto™ in Patients with Low-Grade Upper Tract Urothelial Cancer

PRINCETON, N.J. --(BUSINESS WIRE)--May 15, 2020-- UroGen Pharma Ltd. (Nasdaq:URGN) today announced the presentation of positive data from the UGN-101 ( Jelmyto™ (mitomycin) for pyelocalyceal solution) Phase 3 OLYMPUS trial in patients with low-grade upper tract urothelial cancer (LG-UTUC).

May 07, 2020

UroGen Pharma Reports First Quarter 2020 Financial Results and Recent Corporate Developments

Received U.S. FDA Approval for Jelmyto™, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) Jelmyto Launch on Track for June 1, 2020 Reported UGN-102 Phase 2b Trial Interim Data with 65% Complete Response at Three Months and 85% Durability

May 01, 2020

UroGen Pharma to Report First Quarter 2020 Financial Results On Thursday, May 7, 2020

Conference Call and Webcast Scheduled for Thursday, May 7, 2020 at 8:30 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--May 1, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients

Apr 30, 2020

The Lancet Oncology Publishes Details of UroGen Pharma’s Pivotal OLYMPUS Trial

59% Complete Response in patients with low-grade upper tract urothelial cancer Kaplan-Meier analysis, based on interim data, estimated 12-month durability at 84% Results supported recent U.S. FDA expedited approval of Jelmyto ™ as the first non-surgical treatment for patients with this

Apr 15, 2020

UroGen Pharma Receives U.S. FDA Expedited Approval for Jelmyto™, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer

Approval Based on Phase 3 Trial Results Showing a Complete Response Rate of 58% Median Duration of Response Has Not Been Reached Therapy Provides an Effective, Kidney-Sparing Option for Patients With This Rare and Difficult-To- Treat Cancer First-in-Class Approval Validates UroGen’s Innovative

Apr 03, 2020

UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer

Complete Response (CR) Rate of 65% at Three Months Of those with CR, 97% and 85% of Patients Remained Free of Disease at Six and Nine Months Follow-Up, Respectively Detailed Results Presentation to be Shared Virtually via American Urological Association (AUA) in mid-May PRINCETON, N.J.

Mar 23, 2020

UroGen Pharma Promotes Key Personnel Focused on Commercial Operations and Expanded Clinical Development

Experienced Leadership Team with Established Track Record Prepares for Transition to a Commercial Stage Organization NEW YORK --(BUSINESS WIRE)--Mar. 23, 2020-- UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and

Mar 06, 2020

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK --(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units (“RSUs”) to

Mar 02, 2020

UroGen Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments

Prescription Drug User Fee Act (PDUFA) Goal Date of April 18 th for UGN-101 in Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Experienced Commercial Team Hired and Prepared for Planned UGN-101 Approval and Launch in Q2 Conference Call and Webcast to be held Today at 8:30 AM ET NEW

Current page 1
Page 2
Next page
Last page

Investors

Investors

News Releases

News Releases

Investors

Investors

Urogen - Investor Relations

News Releases

News Releases

Urogen - Tools

Follow us on